ShiraTronics notes the financing was provided by Breakout Ventures (BOV). BOV joins previous Series A lead investors USVP, Amzak Health, and Strategic HealthCare Investment Partners (S.H.I.P), with participation from Aperture Ventures, LivaNova PLC, and a leading Academic Institution.
“Breakout Ventures backs bold companies bringing the strongest scientific insights to bear on important problems. ShiraTronics’ approach builds on years of clinical evidence for the effectiveness of neuromodulation, when properly administered, in the treatment of chronic migraine. We believe the time is right to build a safe, convenient system dedicated to this purpose and that the team behind it has the experience needed to succeed,” said Lindy Fishburne, Breakout Ventures’ Managing Partner. “We are honored to join an investor syndicate with deep expertise in commercializing medical devices to further accelerate ShiraTronics’ path to market, and ultimately to patients.”
“We are thrilled to be partnered with such an experienced investor group led by USVP, Amzak, and S.H.I.P. This important financing from Breakout Ventures provides us additional resources needed to develop and advance a novel therapy for migraine headache in the clinic,” said Lynn Elliott the President and Chief Executive Officer of ShiraTronics.
“Our therapy under development for migraine, a condition that disproportionately impacts women, has the potential to positively impact the lives of millions of patients worldwide. We warmly welcome the addition of Breakout Ventures to this world-class consortium of investors to further develop this valuable therapy,” said Mudit K. Jain, Ph.D., a co-founder and Chairman of the Board of ShiraTronics.
